MA-ULTIVUE
9.3.2022 11:02:08 CET | Business Wire | Press release
Ultivue, Inc., an industry leader in multiplexing tools and novel image analysis solutions for tissue biomarker studies, and Aignostics GmbH, a global leader in Artificial Intelligence (AI) powered precision diagnostics focused on pathology to assist with research, clinical trials and CDx development, announced a partnership to collaborate on the co-development of AI-powered spatial multiplexed immunophenotype solutions for translational research groups and Biopharma.
The companies have already been working together since early 2021 to adapt Aignostics’ client platform to support visualization and analysis for some of Ultivue’s products and services, as well as provisioning of results and corresponding reports. The resulting co-developed platform will now be made available to joint clients. Additionally, proof of concept work conducted on the Ultivue 12-plex Immunophenotyping biomarker panel in over 1,000 clinical NSCLC cases has demonstrated encouraging results for the capacity of AI-based analysis of multiplexed images for more consistent and reproducible readouts at scale. These results will be published later this year and respective AI models made available via the platform.
The companies are now expanding their relationship under a co-marketing agreement to offer the multiplex immunofluorescence (mIF) platform to their respective biotech and pharma clients, initially for research use, with a GCP-compliant version to follow later this year. Moreover, Ultivue and Aignostics will offer AI-powered image analysis services within the platform via Aignostics “Explainable AI” approach for the consistent and precise analysis of mIF cohorts at scale, for both translational research and clinical trial research services in Ultivue’s CLIA accredited clinical research laboratory. “We are excited to extend our workflow offering to include mIF AI for highly automated image analysis by partnering with Aignostics,” says Florian Leiss, VP Digital Health at Ultivue. “Improved viewing capabilities enable us to interactively explore the interplay of mIF-labeled cell populations in the histological context of same-slide H&E.”
“We believe that development of Ultivue’s assays with our AI-powered image analysis will create insights from data at scale that are unprecedented in spatial biology today. We are excited to start offering this approach to our clients for translational science and clinical trials,” said Viktor Matyas, CEO of Aignostics.
Besides offering research and development services to its clients, Ultivue and Aignostics will also develop products for standardized analysis of certain Ultivue products, paving the way for more widespread use of these technologies in both clinical trials and clinical routine.
About Ultivue
Ultivue provides researchers and scientists in translational medicine with multiplex biomarker assays for tissue phenotyping and digital pathology. Its proprietary InSituPlex® technology enables advanced exploration and interrogation of tissue samples for precision medicine research. These highly customizable solutions coupled with our scientific consultative approach strengthen and accelerate biomarker discovery and drug development programs. Learn more at Ultivue.com.
About Aignostics
Aignostics, a Berlin based company with offices in the US, is a digital pathology company dedicated to novel precision diagnostics through the use of a proprietary “Explainable AI” platform in pre-clinical and translational research and clinical trials. The use of such technology is expected to be crucial to implementation of AI-powered algorithms in routine diagnostics in order to verify (explain) the model’s decision outputs. Additionally, through its close alignment to Charité and TU Berlin amongst other collaborators, only Aignostics offers the combination of data access, sample testing and pathology expertise to develop digital pathology algorithms spanning multi-modal biomarker assay detection systems such as H&E, IHC and mIF, amongst others.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220309005149/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TestMu AI Introduces DevTools Assertions in Kane CLI, Enabling Browser-Level Validation Through Natural Language16.6.2026 14:30:00 CEST | Press release
New capability allows developers and AI agents to validate network activity, console logs, browser storage, and performance metrics without writing custom scripts TestMu AI (formerly LambdaTest), the world's first Agentic AI-powered Quality Engineering platform, today announced DevTools Assertions for Kane CLI, enabling developers and AI agents to validate browser internals using natural language. Traditional browser automation focuses on what users can see: buttons, forms, text, and visual states. However, modern web applications depend heavily on browser activity that remains invisible to users, including network requests, API responses, console logs, cookies, local storage, and performance metrics. With DevTools Assertions, Kane CLI extends browser validation beyond the UI, allowing teams to verify these underlying signals using plain-English objectives. Developers can now write objectives such as: "Click Add to Cart and assert the request to /api/cart returned status 200." "Run the
Allegro DVT’s Pulsar Decoder IP Adds Support for AV2 Video Codec16.6.2026 14:30:00 CEST | Press release
Allegro DVT, the leader in Semiconductor Video IPs and Video Compliance Tools, announces the availability its real-time AV2 Decoder IP integrated into its Pulsar™ D400 Series Multi-Standard Decoding IP. This milestone is a follow-up to the company’s announcement in September 2026 that underscored its plans to develop solutions for the emerging AV2 ecosystem spanning both video compliance tools and semiconductor IPs. As global demand for high-quality streaming continues to accelerate, AV2 is emerging as the next major open, royalty-free video compression standard. Developed by the Alliance for Open Media (AOM), AV2 represents a generational leap in video coding, designed to address evolving streaming requirements and enable new media experiences. Building on the success of AV1, AV2 introduces capabilities that support advanced applications such as immersive content (AR/VR), multi-view and split-screen streaming, and improved screen content handling, while operating across a wider range
Sai Life Sciences Achieves EcoVadis Platinum Rating, Joining the Top 1% of Companies Assessed Worldwide16.6.2026 14:27:00 CEST | Press release
Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), one of India’s leading integrated contract research, development, and manufacturing organizations (CRDMOs) has secured the EcoVadis Platinum Rating 2026, placing it among the top 1% of companies assessed worldwide for sustainability performance. With an overall score of 87/100 and a 99th percentile ranking, Sai Life Sciences has achieved Platinum Medal in ‘Manufacture of Basic Pharmaceutical Products and Pharmaceutical Preparations’ category. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260616260047/en/ Sai Life Sciences achieves EcoVadis Platinum Rating, joining the top 1% of companies assessed worldwide Making the announcement, Krishna Kanumuri, CEO & Managing Director, Sai Life Sciences, said, “Sustainability is becoming one of the defining measures of excellence in our industry. The ability to innovate, grow and create impact must be matched by an equal commitment
Plaud Scales From $1M to $100M ARR Within Two Years, Bringing AI Beyond the Screen for Professionals16.6.2026 14:25:00 CEST | Press release
Among the fastest-known AI companies, Plaud stands out as a rare hardware-enabled AI company in a cohort dominated by software-only players. Plaud, the company building real-world AI interface for professionals, today announced it has scaled from $1M to $100M in ARR within two years, placing it among the fastest AI companies globally to reach the milestone. Plaud is the only hardware-enabled AI company in a cohort otherwise dominated by software-only players, and now serves more than 2 million professionals across 170+ countries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260616945160/en/ The fastest AI growth stories have, until now, belonged almost entirely to software-native companies: AI coding tools, enterprise workflow agents, and other SaaS products scaling behind screens and keyboards. Plaud's growth represents a different model — recurring AI software scaled through a real-world physical interface, with devices
Rehlko Integrates WB Power Services into its UK and EMEA Platform, Expanding Lifecycle Capabilities for Mission-Critical Power16.6.2026 14:00:00 CEST | Press release
Rehlko, a global energy resilience leader delivering innovative solutions across industrial energy systems, powertrain technologies, and home energy applications, today announced that its UK business, formerly WB Power Services, has been fully brought onto the Rehlko platform, strengthening the company’s UK and Europe, Middle East, and Africa (EMEA) operating model and expanding its ability to deliver end-to-end lifecycle solutions for mission-critical power applications. The move aligns the former WB Power Services’ long-established UK capabilities – including engineering, installation, commissioning, and long-term service – with Rehlko’s broader platform. It represents an important step in scaling consistent, high-quality delivery across priority markets as demand accelerates in data centers and other mission-critical environments. Customers increasingly require partners that can deliver reliable, repeatable solutions across the full project lifecycle and over long operating horizons
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom